Sapablursen and ION356 granted fast track designation by the FDA for the treatment of patients with polycythemia vera (PV) and Pelizaeus-Merzbacher disease (PMD), respectively ...

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono March 12, 2025 — 07:54 am EDT. ... an investigational RNA-based therapy for polycythemia vera (PV).

The therapeutic approach in polycythemia vera is to reduce the risk of thromboembolic events by maintaining a hematocrit of less than 45%. 9-11 Current treatments for polycythemia vera are based ...

Emerging treatments like rusfertide may reduce phlebotomies and improve life for patients with polycythemia vera, according ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global ...

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Blood cancers, a category that includes polycythemia vera (PV), are a risk factor for severe COVID-19. As such, managing your risk and taking steps to prevent COVID-19 if you have PV are important ...